About the company
Tiziana Life Sciences Ltd is a leading clinical-stage biotechnology company dedicated to bringing innovative and transformative therapies to patients suffering from various complex diseases. With a particular focus on autoimmune and inflammatory diseases, degenerative diseases, and liver cancer, the company aims to provide novel treatment options that can make a significant difference in patients' lives. One of the key areas of Tiziana's research and development efforts is Crohn's Disease, a chronic inflammatory bowel disease that affects millions of people worldwide. Tiziana is committed to developing a targeted therapy for this debilitating condition, addressing the underlying causes and offering potential relief to patients. In light of the global COVID-19 pandemic, Tiziana has also directed its resources towards the development of a potential treatment for this highly infectious disease. Leveraging their expertise in immunology, the company has initiated clinical trials for a COVID-19 therapy, exploring the possibility of modulating the immune system to combat the virus effectively. Recognizing the urgent need for effective treatments for multiple sclerosis (MS), Tiziana has focused its efforts on Secondary Progressive Multiple Sclerosis (SPMS). Through their drug asset in the clinical pipeline, the company aims to develop a therapy that can slow down disease progression and improve patient outcomes, providing hope for those living with this debilitating neurological disorder. Another area of focus for Tiziana Life Sciences is Hepatocellular Carcinoma (HCC), the most common form of liver cancer. With a high unmet medical need in this area, the company is committed to developing innovative therapeutic options that can improve patient survival rates and enhance their quality of life. The company's development pipeline includes several promising drug assets. Foralumab, a fully human monoclonal antibody targeting the CD3 receptor, is one of the key candidates being investigated for various indications, including Crohn's Disease and multiple sclerosis. This innovative therapy has the potential to modulate immune responses and reduce inflammation. Milciclib, another notable drug asset in Tiziana's portfolio, is a small molecule inhibitor of multiple cyclin-dependent kinases (CDKs) that play a crucial role in regulating cell cycle progression. By inhibiting these kinases, Milciclib has the potential to disrupt cancer cell growth and proliferation, offering a promising option for the treatment of various solid tumors. The company is also exploring the potential of an Anti-IL6R monoclonal antibody, which targets the interleukin-6 receptor, a key player in the inflammatory response. This therapy has the potential to modulate the excessive immune responses seen in many autoimmune and inflammatory diseases, providing much-needed relief to affected patients. With a strong focus on research and development, Tiziana Life Sciences operates within a single reporting segment. The company is dedicated to advancing biotechnological and pharmaceutical products through the discovery of innovative therapies and their subsequent development and clinical testing. By continuously expanding and refining their pipeline, Tiziana aims to bring groundbreaking treatments to patients in need, making a lasting impact on healthcare.
Website: https://www.tizianalifesciences.com
Data updated: June 2, 2026
